Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 645

1.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
2.
3.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA.

J Clin Pathol. 2009 Feb;62(2):139-46. doi: 10.1136/jcp.2008.056291. Epub 2008 Aug 4.

PMID:
18682421
4.

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium.

Clin Cancer Res. 2005 Jul 15;11(14):5175-80.

5.

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.

Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y.

BMC Cancer. 2008 Oct 25;8:309. doi: 10.1186/1471-2407-8-309.

6.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
7.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

8.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

9.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
10.

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH.

Mod Pathol. 2010 Jan;23(1):123-33. doi: 10.1038/modpathol.2009.145. Epub 2009 Oct 23.

11.

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.

Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.

Clin Cancer Res. 2005 Jun 1;11(11):4003-11.

12.

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.

Hum Pathol. 2006 Sep;37(9):1217-26. Epub 2006 Jul 18.

PMID:
16938528
13.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
14.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
15.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683
16.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.

PMID:
14519755
17.
18.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.

PMID:
16541313
19.

Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.

Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, Nassar A.

Hum Pathol. 2009 Aug;40(8):1176-81. doi: 10.1016/j.humpath.2009.01.003. Epub 2009 Apr 14.

PMID:
19368951
20.

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO.

Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.

Supplemental Content

Support Center